Sign up Australia
Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals’ medicinal cannabis plants enter flowering phase

The harvesting of the plants will commence in the next 2 weeks.
cannabis cultivation
The biomass will be processed into cannabidiol crystals

MGC Pharmaceuticals Ltd’s (ASX:MXC) Czech Republic operation is progressing well with over 450 medicinal cannabis plants entering the flowering phase.

The growth and yield from the plants have been better than expected (for a first time crop) in the new 1,100 square metre glass house facility.

Importantly, the harvesting of the plants will commence in the next 2 weeks.

Once harvested, biomass will be processed into CBD (cannabidiol) crystals for MGC’s products including the MGC Derma cosmetics and for the company’s clinical studies.

The remaining biomass will be sold as Aquiol, a rich >98% CBD purity raw material.

MGC’s botanic division’s collaboration with the University of Ljubljana is also progressing on schedule in Slovenia.

Following the planting of medicinal cannabis seeds for a genetic research program in June 2017, the plants have now progressed to the flowering phase.

The program aims to create genetic strains with high levels of CBD and new strains with high tetrahydrocannabinol (THC) levels for the treatment of specific disease symptoms.

The team will now commence a research project which will focus on the implementation and optimisation of molecular markers for sex determination and distinction between strains.

MGC’s raw material production at its open field farm in Slovenia has also delivered encouraging production volumes.

As planned, the company has completed harvesting of its cannabis crops, yielding 4,000 kilograms of biomass in early October 2017.





Register here to be notified of future MXC Company articles
View full MXC profile View Profile

MGC Pharmaceuticals Timeline

Related Articles

Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
picture of drug research
August 23 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use